In an FDA approved study (ClinicalTrials.gov NCT00607230) the group led by Dr Faustman demonstrated the efficacy in immunomodulating the innate immunity response as increases in dead insulin-autoreactive T cells and induction of Tregs which translated in an increased of C peptide levels in a small grroup of patients (n=6) monitored for 20 weeks.

Is anyone aware of recent data on the use of BCG as longer term therapy for DMt1? Any oppinions about the possible efficacy for long term through immunomodulation? Possible drawbacks due to side effects ( increased TNFalpha, Eppstein Barr infection)?

Thanks.

More Michaela Yakubovich-Dirks's questions See All
Similar questions and discussions